- Home
- STTK vs PBYI Comparison
STTK vs PBYI Comparison
Compare STTK & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- PBYI
- Stock Information
- Founded
- STTK 2016
- PBYI 2010
- Country
- STTK United States
- PBYI United States
- Employees
- STTK N/A
- PBYI N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- STTK Health Care
- PBYI Health Care
- Exchange
- STTK Nasdaq
- PBYI Nasdaq
- Market Cap
- STTK 37.6M
- PBYI 164.3M
- IPO Year
- STTK 2020
- PBYI N/A
- Fundamental
- Price
- STTK $0.83
- PBYI $3.54
- Analyst Decision
- STTK Hold
- PBYI Strong Buy
- Analyst Count
- STTK 4
- PBYI 1
- Target Price
- STTK $3.00
- PBYI $7.00
- AVG Volume (30 Days)
- STTK 401.7K
- PBYI 306.9K
- Earning Date
- STTK 07-31-2025
- PBYI 07-31-2025
- Dividend Yield
- STTK N/A
- PBYI N/A
- EPS Growth
- STTK N/A
- PBYI 143.51
- EPS
- STTK N/A
- PBYI 0.77
- Revenue
- STTK $4,606,000.00
- PBYI $232,709,000.00
- Revenue This Year
- STTK N/A
- PBYI N/A
- Revenue Next Year
- STTK N/A
- PBYI N/A
- P/E Ratio
- STTK N/A
- PBYI $4.64
- Revenue Growth
- STTK 69.65
- PBYI 2.68
- 52 Week Low
- STTK $0.69
- PBYI $2.23
- 52 Week High
- STTK $4.99
- PBYI $4.13
- Technical
- Relative Strength Index (RSI)
- STTK 39.19
- PBYI 58.27
- Support Level
- STTK $0.77
- PBYI $3.26
- Resistance Level
- STTK $0.91
- PBYI $3.65
- Average True Range (ATR)
- STTK 0.08
- PBYI 0.14
- MACD
- STTK -0.02
- PBYI 0.01
- Stochastic Oscillator
- STTK 16.23
- PBYI 82.83
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.